Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (149414)	6/27/2019 5:34:53 AM
From: THE ANT	1 Recommendation Recommended By Julius Wong Read Replies (1) \| Respond to of 218050

SRPT will have an interesting day this Friday. Their competitor in DMD gene therapy is Pfizer and they will give data on their progress this Friday. Pfizer is using 3X the viral vector load that SRPT does and the more virus the more immune response issues. The rumors are the AAV9 vector they are using is already causing trouble in kids.SRPT uses a different vector with proven success 1/3 the viral load and no side effects to date. With any bad Pfizer results SRPT goes to the moon. If SRPT falls you can buy it as they clearly have the lead, the better science, the better relationship with the families and the better ethics